GH Research (GHRS) Net Cash Flow (2020 - 2025)
GH Research (GHRS) posted quarterly Net Cash Flow of -$3.6 million for Q4 2025, down 132.87% year-over-year from $10.8 million in Q4 2024, and up 10.24% quarter-over-quarter from -$4.0 million in Q3 2025.
GH Research (GHRS) Net Cash Flow (2020 - 2025) Analysis & Trends
GH Research's Net Cash Flow history runs 6 years deep, the most recent figure standing at -$3.6 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 132.87% year-over-year to -$3.6 million; the TTM figure through Dec 2025 stood at $142.3 million (up 531.03% YoY), while the FY2025 annual figure was $142.3 million, up 531.03% from the prior year.
- Net Cash Flow for Q4 2025 stood at -$3.6 million, up from -$4.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $194.6 million in Q4 2022, with the low at -$61.0 million in Q1 2023.
- The 5-year median for Net Cash Flow is -$3.8 million (2021), against an average of $11.7 million.
- The sharpest annual moves came in 2021 and 2025: Net Cash Flow slumped 15309.09% in 2021, then soared 16496.25% in 2025.
- GH Research's Net Cash Flow stood at -$3.9 million in 2021, then surged by 5029.94% to $194.6 million in 2022, then tumbled by 106.03% to -$11.7 million in 2023, then soared by 192.18% to $10.8 million in 2024, then sank by 132.87% to -$3.6 million in 2025.
- Business Quant data shows GHRS's Net Cash Flow at -$3.6 million in Q4 2025, -$4.0 million in Q3 2025, and $5.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.56 Mn |
| Dec 31, 2025 | -3.56 Mn |
| Sep 30, 2025 | -3.96 Mn |
| Sep 30, 2025 | -3.96 Mn |
| Jun 30, 2025 | 5.67 Mn |
| Jun 30, 2025 | 5.67 Mn |
| Mar 31, 2025 | 144.12 Mn |
| Mar 31, 2025 | 144.12 Mn |
| Dec 31, 2024 | 10.83 Mn |
| Dec 31, 2024 | 10.83 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 9.68 Mn |
| Jun 30, 2024 | 9.68 Mn |
| Mar 31, 2024 | -879,000.00 |
| Mar 31, 2024 | -879,000.00 |
| Dec 31, 2023 | -11.74 Mn |
| Dec 31, 2023 | -11.74 Mn |
| Sep 30, 2023 | -10.35 Mn |
| Sep 30, 2023 | -10.35 Mn |